Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial

Eva Versteijne, Mustafa Suker, Karin Groothuis, Janine M. Akkermans-Vogelaar, Marc G. Besselink, Bert A. Bonsing, Jeroen Buijsen, Olivier R. Busch, Geert-Jan M. Creemers, Ronald M. van Dam, Ferry A. L. M. Eskens, Sebastiaan Festen, Jan Willem B. de Groot, Bas Groot Koerkamp, Ignace H. de Hingh, Marjolein Y. Homs, Jeanin E. van Hooft, Emile D. Kerver, Saskia A. C. Luelmo, Karen J. NeelisJoost Nuyttens, Gabriel M. R. M. Paardekooper, Gijs A. Patijn, Maurice J. C. van der Sangen, Judith de Vos-Geelen, Johanna W. Wilmink, Aeilko H. Zwinderman, Cornelis J. Punt, Casper H. van Eijck, Geertjan van Tienhoven*, Dutch Pancreatic Canc Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1763-1773
Number of pages12
JournalJournal of Clinical Oncology
Volume38
Issue number16
DOIs
Publication statusPublished - 1 Jun 2020
Event54th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, United States
Duration: 1 Jun 20185 Jun 2018

Keywords

  • FULL-DOSE GEMCITABINE
  • NEOADJUVANT CHEMORADIATION
  • ADJUVANT CHEMOTHERAPY
  • DUCTAL ADENOCARCINOMA
  • CONCURRENT RADIATION
  • OPEN-LABEL
  • THERAPY
  • MULTICENTER
  • FOLFIRINOX
  • SURVIVAL

Cite this